🇺🇸 FDA
Patent

US 11060089

Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

granted A61KA61K31/7105A61K9/0019

Quick answer

US patent 11060089 (Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene) held by Sarepta Therapeutics, Inc. expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/7105, A61K9/0019, A61K9/0053, A61P